A novel process for the synthesis of 1-aryl-1-trifluoromethylcyclopropanes
US-2019375702-A1 · Dec 12, 2019 · US
Pharmaceutical combination comprising a T-type calcium channel blocker
US11213517B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11213517-B2 |
| Application number | US-201716470109-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 15, 2017 |
| Priority date | Dec 16, 2016 |
| Publication date | Jan 4, 2022 |
| Grant date | Jan 4, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a pharmaceutical combination comprising a first active ingredient which is N-[1-(5-Cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide or a pharmaceutically acceptable salt thereof and a second active ingredient which has an anti-epileptic effect, or a pharmaceutically acceptable salt thereof.
First claim
Opening claim text (preview).
The invention claimed is: 1. A pharmaceutical combination comprising a first active ingredient which is N-[1-(5-Cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide or a pharmaceutically acceptable salt thereof and a second active ingredient selected from the group consisting of (S)-2-(2-oxopyrrolidin-1-yl)butanamide and 2-propylpentanoic acid, or a pharmaceutically acceptable salt of any of the aforementioned. 2. The pharmaceutical combination according to claim 1 , wherein the second active ingredient is (S)-2-(2-oxopyrrolidin-1-yl)butanamide or a pharmaceutically acceptable salt thereof. 3. The pharmaceutical combination according to claim 1 , wherein the second active ingredient is 2-propylpentanoic acid or a pharmaceutically acceptable salt thereof. 4. The pharmaceutical combination according to claim 1 , wherein the first and the second active ingredient are comprised in a single pharmaceutical composition. 5. The pharmaceutical combination according to claim 1 , wherein the first and the second active ingredient are comprised in separated pharmaceutical compositions. 6. A method of treating epilepsy in a patient in need thereof, comprising administering to the patient a pharmaceutical combination according to claim 1 . 7. A method of treating tonic clonic seizures, absence seizures, or a combination thereof, in a patient in need thereof, comprising administering to the patient a pharmaceutical combination according to claim 1 . 8. A kit of parts comprising a first pharmaceutical composition comprising, as an active ingredient, N-[1-(5-Cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide, or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient; and a second pharmaceutical composition comprising an active ingredient selected from the group consisting of (S)-2-(2-oxopyrrolidin-1-yl)butanamide and 2-propylpentanoic acid, or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient.
Assignees
Inventors
Classifications
Antiepileptics; Anticonvulsants · CPC title
Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
1,4-Benzodiazepines, e.g. diazepam {or clozapine} · CPC title
having two nitrogen atoms, e.g. dilazep · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11213517B2 cover?
- The present invention relates to a pharmaceutical combination comprising a first active ingredient which is N-[1-(5-Cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide or a pharmaceutically acceptable salt thereof and a second active ingredient which has an anti-epileptic effect, or a pharmaceutically acceptable salt thereof.
- Who is the assignee on this patent?
- Idorsia Pharmaceuticals Ltd
- What technology area does this patent fall under?
- Primary CPC classification A61K31/55. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 6 related publications on this page (citations in our corpus or others sharing the same primary CPC).